Novolog (NVLG) AI Stock Analysis

• Market Cap: 661.07M
• Dividend Yield: 3.03%
• Average Volume (3M): 787.95K
• Price to Earnings (P/E): 32.9
• Beta (1Y): 0.78
• Revenue Growth: 25.00%
• EPS Growth: N/A
• Country: IL
• Employees: 936
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.90
• Shares Outstanding: 510,874,760
• 10 Day Avg. Volume: 1,118,680
• 30 Day Avg. Volume: 787,950
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: 145.00
• Price Target Upside: 12.06% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 56 Neutral
• Price Target: 145.00 ▲(12.06% Upside)

The overall stock score is primarily influenced by financial performance challenges, particularly in profitability and cash flow. Technical analysis indicates a bearish trend, and valuation metrics suggest the stock may be overvalued. The absence of earnings call data and corporate events means these factors did not influence the score.

Novolog Business Overview & Revenue Model

Company Description

Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. It offers medical devices to healthcare institutions and patients in their homes; and medical logistics services to pharmaceutical and medical device companies. The company also produces and disseminates medical content and tools to the general public and medical community; and develops personalized treatment programs and initiates home visits by nurses. In addition, it provides health and medical process management services for corporations; and supplies sterilization services using ethylene oxide gas for medical and laboratory products, as well as offers direct access to health and wellness ecosystem for international corporations. The company is based in Modi'in-Maccabim-Re'ut, Israel.

How the Company Makes Money

Novolog makes money primarily through service fees charged for its logistics and supply chain management services. The company's revenue model includes charging clients for warehousing and storage solutions, transportation and distribution services, and supply chain consultancy. Novolog may also generate income from value-added services such as temperature-controlled logistics and inventory management solutions. Strategic partnerships with pharmaceutical companies and healthcare providers play a crucial role in securing long-term contracts, providing a steady stream of revenue. Additionally, Novolog's investment in technology enables it to offer data-driven insights and analytics services, which can be an additional source of income.

Novolog Financial Statement Overview

Summary

Novolog exhibits strong revenue growth and improving profitability, with a stable balance sheet and moderate leverage. However, the recent decline in free cash flow and equity warrants attention, indicating potential liquidity issues if not addressed.

Income Statement

Novolog has demonstrated consistent revenue growth, with a notable increase from $1.13 billion in 2020 to $2.09 billion in TTM 2025. The gross profit margin has been relatively stable, though it slightly decreased in the TTM period. The net profit margin has improved, turning positive after a negative period in 2023, indicating better cost management. However, the EBIT margin has shown some volatility, suggesting potential operational challenges.

Balance Sheet

The company's debt-to-equity ratio is moderate, reflecting a balanced approach to leveraging. Stockholders' equity has been stable, though it decreased slightly in the TTM period. The equity ratio indicates a solid foundation, but the decreasing trend in equity could be a concern if it continues. Overall, the balance sheet shows a stable financial position with manageable debt levels.

Cash Flow

Novolog's operating cash flow has been strong, though it decreased significantly in the TTM period. The free cash flow turned negative in the TTM period, which could indicate potential liquidity issues if not addressed. The operating cash flow to net income ratio remains healthy, suggesting that the company is effectively converting its earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.09B	2.02B	1.64B	1.51B	1.26B	1.13B
Gross Profit	164.09M	180.78M	173.76M	176.15M	148.96M	129.29M
EBITDA	117.18M	149.39M	130.14M	138.53M	115.92M	104.05M
Net Income	27.37M	39.54M	-42.00M	47.51M	42.32M	40.07M
Balance Sheet
Total Assets	3.12B	3.04B	2.79B	2.43B	2.29B	2.19B
Cash, Cash Equivalents and Short-Term Investments	111.22M	247.60M	232.94M	172.81M	238.71M	176.44M
Total Debt	191.08M	198.47M	215.18M	212.77M	166.81M	154.24M
Total Liabilities	2.73B	2.65B	2.39B	1.97B	1.86B	1.89B
Stockholders Equity	370.37M	368.38M	371.08M	436.00M	424.37M	294.69M
Cash Flow
Free Cash Flow	-3.47M	99.78M	129.06M	63.16M	52.75M	32.87M
Operating Cash Flow	62.91M	158.52M	200.01M	132.65M	83.39M	58.48M
Investing Cash Flow	-58.84M	-50.55M	-72.60M	-124.95M	-69.07M	-28.61M
Financing Cash Flow	-94.14M	-94.59M	-67.71M	-72.96M	47.49M	-39.85M

Novolog Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 129.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NVLG, the sentiment is Negative. The current price of 129.4 is below the 20-day moving average (MA) of 140.27, below the 50-day MA of 139.76, and below the 200-day MA of 153.65, indicating a bearish trend. The MACD of -4.24 indicates Positive momentum. The RSI at 36.79 is Neutral, neither overbought nor oversold. The STOCH value of 14.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:NVLG.

Novolog Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BWAY	78 Outperform	961.20M	48.30	4.69%	―	23.45%	670.44%
DANE	62 Neutral	2.97B	139.05	4.64%	2.27%	7.37%	2.40%
NVLG	56 Neutral	661.07M	32.93	―	3.03%	25.00%	―
SOFW	46 Neutral	943.38M	-147.00	-6.13%	―	22.30%	59.78%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%